BiotechTube
Oxford Biomedica

Oxford Biomedica

OXB.L
Oxford, United Kingdom· Est. 1995

Oxford Biomedica is a UK-based, publicly traded CDMO that has established itself as a world leader in viral vector manufacturing for advanced cell and gene therapies. The company has transitioned to a pure-play CDMO model, leveraging its deep expertise and proprietary platforms to serve a global client base. With state-of-the-art facilities in the UK, US, and France, and a track record of over 30 years, OXB is a critical enabler for the development and commercialization of life-changing therapies, including being the first commercial supplier of lentiviral vectors for a CAR-T therapy.

oxb.com

OXB.L · Stock Price

USD 593.00+284.50 (+92.22%)
Market Cap: $961.9M

Historical price data

AI Company Overview

Oxford Biomedica is a UK-based, publicly traded CDMO that has established itself as a world leader in viral vector manufacturing for advanced cell and gene therapies. The company has transitioned to a pure-play CDMO model, leveraging its deep expertise and proprietary platforms to serve a global client base. With state-of-the-art facilities in the UK, US, and France, and a track record of over 30 years, OXB is a critical enabler for the development and commercialization of life-changing therapies, including being the first commercial supplier of lentiviral vectors for a CAR-T therapy.

OncologyRare DiseasesNeurologyOphthalmologyHematology

Technology Platform

Proprietary LentiVector™ platform for lentiviral vectors and inAAVate™ platform for AAV vectors, offering optimized, scalable, and validated processes for cell and gene therapy development and manufacturing.

Pipeline

12
12 drugs in pipeline
DrugIndicationStageWatch
TroVax + IL-2Carcinoma, Renal CellPhase 2
TroVax + Interleukin-2Carcinoma, Renal CellPhase 2
TroVax® + PlaceboOvarian CancerPhase 2
TroVaxColorectal NeoplasmsPhase 2
Docetaxel + TroVaxHormone Refractory Prostate CancerPhase 2

Opportunities

The company is poised for growth driven by the global expansion of cell and gene therapy pipelines, which face a critical shortage of viral vector manufacturing capacity.
Strategic opportunities include leveraging its new US-based facility in Durham to capture late-stage and commercial programs, and expanding its geographic reach through platform licensing deals like the one with VVMF in the fast-growing APAC region.

Risk Factors

Key risks include client concentration, the technical complexity and execution risk of viral vector manufacturing, stringent regulatory oversight of facilities, intense competition in the CDMO space, and dependence on the overall funding and success of the cell and gene therapy sector.

Competitive Landscape

OXB competes with large, diversified CDMOs like Lonza and Thermo Fisher, as well as other bioprocessing specialists. Its differentiation lies in its pure-play focus on viral vectors, over 30 years of pioneering expertise, proprietary and validated platform technologies (LentiVector™, inAAVate™), and a proven track record of supporting a therapy from development to global commercial launch.